Trials / Active Not Recruiting
Active Not RecruitingNCT06179511
Study of AZD9829 in CD123+ Hematological Malignancies
A Modular Phase I/II, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of AZD9829 as Monotherapy or in Combination in Patients With CD123-Positive Hematological Malignancies
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 56 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a modular, multicentre, open-label, Phase I/II, dose-setting study. AZD9829 will be administered intravenously as monotherapy or in combination in participants with CD123 positive hematological malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD9829 | AZD9829 will be administered by IV infusion |
| DRUG | AZD9829 | AZD9829 will be administered by IV infusion |
Timeline
- Start date
- 2024-01-31
- Primary completion
- 2025-10-31
- Completion
- 2026-03-23
- First posted
- 2023-12-22
- Last updated
- 2026-01-29
Locations
22 sites across 10 countries: United States, Australia, China, Germany, Italy, Japan, South Korea, Spain, Taiwan, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06179511. Inclusion in this directory is not an endorsement.